MedTrace Logo

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

NCT00321633 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2013-08-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether carboplatin is more effective than docetaxel in treating patients with metastatic genetic breast cancer.

PURPOSE: This randomized phase II trial is studying carboplatin to see how well it works compared to docetaxel in treating women with metastatic genetic breast cancer.

Conditions

  • brca1 Mutation Carrier
  • brca2 Mutation Carrier
  • Breast Cancer
  • Hereditary Breast/Ovarian Cancer (brca1, brca2)

Interventions

DRUG

carboplatin

DRUG

docetaxel

Sponsors & Collaborators

  • University College London Hospitals

    lead OTHER

Principal Investigators

  • Andrew Tutt, MD, PhD, FRCR, MBBS, MRCP · Guy's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2009-09-30

Countries

  • Australia
  • Israel
  • Portugal
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00321633 on ClinicalTrials.gov